Tango Therapeutics
TNGX
36 hedge funds and large institutions have $148M invested in Tango Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
1.46% less ownership
Funds ownership: 63.87% → 62.41% (-1.5%)
5% less capital invested
Capital invested by funds: $156M → $148M (-$7.85M)
8% less funds holding
Funds holding: 39 → 36 (-3)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.73M |
| 2 |
HM
HealthCor Management
New York
|
+$472K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$207K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$117K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.73M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$1.14M |
| 3 |
Janus Henderson Group
London,
|
-$1.12M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$663K |
| 5 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
-$549K |
TNGX Hedge Fund Activity: Q1 2021 in Review
36 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2021, worth a combined $148M — down 5% from $156M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TNGX and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Ikarian Capital, adding an estimated $1.73M. The largest seller was Millennium Management, cutting an estimated $1.73M.
- 36 institutional investors held Tango Therapeutics (TNGX) as of Q1 2021, down from 39 in Q4 2020.
- Funds reported $148M of Tango Therapeutics stock for Q1 2021, down 5% quarter-over-quarter.
- 3 funds opened new Tango Therapeutics positions in Q1 2021 and 6 closed out, a net change of -3 holders.
- The largest Tango Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $1.73M added.
- The largest Tango Therapeutics seller in Q1 2021 was Millennium Management, an estimated $1.73M sold.
Based on aggregated 13F filings for Q1 2021.